Ptc Therapeutics (PTCT) Research & Development (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Research & Development of $99.1 million for Q2 2026, down 12.25% year-over-year from $113.0 million in Q2 2025, and down 1.71% quarter-over-quarter from $100.9 million in Q1 2026.
Ptc Therapeutics (PTCT) Research & Development (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Research & Development history runs 15 years deep, the most recent figure standing at $99.1 million for Q2 2026.
- In Q2 2026, Research & Development fell 12.25% year-over-year to $99.1 million; the TTM figure through Jun 2026 stood at $433.3 million (down 14.73% YoY), while the FY2025 annual figure was $455.2 million, down 14.82% from the prior year.
- Research & Development for Q2 2026 stood at $99.1 million, down from $100.9 million in the prior quarter.
- The five-year high for Research & Development was $195.1 million in Q1 2023, with the low at $99.1 million in Q2 2026.
- The 5-year median for Research & Development is $132.6 million (2024), against an average of $139.3 million.
- The sharpest annual moves came in 2023 and 2024: Research & Development surged 39.3% in 2023, then plunged 40.48% in 2024.
- Ptc Therapeutics' Research & Development stood at $188.7 million in 2022, then tumbled by 35.69% to $121.4 million in 2023, then rose by 2.82% to $124.8 million in 2024, then rose by 6.7% to $133.1 million in 2025, then fell by 25.52% to $99.1 million in 2026.
- Business Quant data shows PTCT's Research & Development at $99.1 million in Q2 2026, $100.9 million in Q1 2026, and $133.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 99.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.15 Mn |
| Mar 31, 2026 | 100.87 Mn |
| Dec 31, 2025 | 133.13 Mn |
| Sep 30, 2025 | 100.16 Mn |
| Jun 30, 2025 | 112.99 Mn |
| Mar 31, 2025 | 108.97 Mn |
| Dec 31, 2024 | 124.77 Mn |
| Sep 30, 2024 | 161.41 Mn |
| Jun 30, 2024 | 132.17 Mn |
| Mar 31, 2024 | 116.13 Mn |
| Dec 31, 2023 | 121.35 Mn |
| Sep 30, 2023 | 164.21 Mn |
| Jun 30, 2023 | 185.87 Mn |
| Mar 31, 2023 | 195.12 Mn |
| Dec 31, 2022 | 188.69 Mn |
| Sep 30, 2022 | 165.46 Mn |
| Jun 30, 2022 | 157.26 Mn |
| Mar 31, 2022 | 140.08 Mn |
| Dec 31, 2021 | 149.84 Mn |
| Sep 30, 2021 | 130.85 Mn |